Drug intelligence / Profile preview

CD19-CD22 CAR-T cells (Institute of Hematology & Blood Diseases Hospital)

Development stage: Unknown
Lead developer: Institute of Hematology and Blood Diseases Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

This is an investigational bispecific CAR-T cell therapy developed by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. The therapy is designed to treat relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) by engineering autologous T-cells to express a chimeric antigen receptor (CAR) that simultaneously targets both CD19 and CD22 antigens. The CAR construct utilizes scFvs derived from hybridoma clones HIB22 and HI19a, linked with a CD8α signal peptide and transmembrane domain, a 4-1BB costimulatory domain, and a CD3ζ cytoplasmic signaling region. This dual-targeting strategy is intended to overcome antigen escape and reduce relapse rates associated with single-target CD19 CAR-T therapies.

Other names: bispecific CD19-CD22 CAR-T cellstandem CD19-CD22 CAR-T cellsCD19-CD22 CAR-T cells-Institute of Hematology & Blood Diseases Hospital, China-B-cell acute lymphoblastic leukemia

Targets

CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on CD19-CD22 CAR-T cells (Institute of Hematology & Blood Diseases Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19-CD22 CAR-T cells (Institute of Hematology & Blood Diseases Hospital).

Explore the full profile